AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 12th, 2009 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is made on the 21st day of April, 2009 (the “Amendment Date”), by and among DUSA Pharmaceuticals, Inc., a company incorporated in the State of New Jersey, having its principal offices at 25 Upton Drive, Wilmington, Massachusetts (“DUSA”), and River’s Edge Pharmaceuticals, LLC, a Georgia limited liability company, having its principal offices at 5400 Laurel Springs Parkway, Building 504, Suwanee, Georgia 30024 (“River’s Edge”).
THIRD AMENDMENT TO MERGER AGREEMENTMerger Agreement • May 12th, 2009 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT TO MERGER AGREEMENT (this “Third Amendment”) is made on the 21st day of April, 2009, by and among DUSA Pharmaceuticals, Inc., a company incorporated in the State of New Jersey, with principal offices at 25 Upton Drive, Wilmington, Massachusetts (“DUSA”), Frank Pollard, residing at 3615 Crestview Drive, Long Grove, IL 60047 and Jeffrey Bernstein, residing at 9739 Monte Mar Drive, Los Angeles, CA 90035 (collectively hereinafter referred to as the “Shareholder Representatives”) and those certain shareholders of the former Sirius Laboratories, Inc., a company incorporated in the State of Illinois (“Sirius Illinois”) set forth on the signature page hereto (each a “Principal Shareholder” and collectively the “Principal Shareholders”). DUSA, the Shareholder Representatives and the Principal Shareholders are at times referred to each as a “Party” and collectively as the “Parties.” All capitalized terms used, but not specifically defined herein, shall have the meaning provi
